UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]

Value in health, 2018-02, Vol.21 (2), p.131-139

2018

Volltextzugriff (PDF)

An Overview of Value, Perspective, and Decision Context—A Health Economics Approach: An ISPOR Special Task Force Report [2]

Value in health, 2018-02, Vol.21 (2), p.124-130

2018

Volltextzugriff (PDF)

Multicriteria Decision Analysis and Value Assessment Frameworks: Where Do We Stand? What Next?

Value in health, 2024-01, Vol.27 (1), p.3-6

Garrison, Jr, Louis P

2024

Volltextzugriff (PDF)

Incorporating Real Option Value in Valuing Innovation: A Way Forward

PharmacoEconomics, 2024-07, Vol.42 (Suppl 2), p.199-210

2024

Volltextzugriff (PDF)

Paying for Kidneys: Reflections on Welfare Economics, Political Economy, and Market Design

Value in health, 2022-12, Vol.25 (12), p.1925-1928

Garrison, Louis P.

2022

Volltextzugriff (PDF)

Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the “Age of Cures” and Their Implications for Dynamic Efficiency

Value in health, 2023-03, Vol.26 (3), p.336-343

2023

Volltextzugriff (PDF)

Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis

Value in health, 2017-02, Vol.20 (2), p.213-216

2017

Volltextzugriff (PDF)

A Health Economics Approach to US Value Assessment Frameworks—Introduction: An ISPOR Special Task Force Report [1]

Value in health, 2018-02, Vol.21 (2), p.119-123

2018

Volltextzugriff (PDF)

Performance-Based Risk-Sharing Arrangements: An Updated International Review

PharmacoEconomics, 2017-10, Vol.35 (10), p.1063-1072

2017

Volltextzugriff (PDF)

Estimating the Allocation of the Economic Value Generated by Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015 to 2019

Value in health, 2024-08, Vol.27 (8), p.1021-1029

2024

Volltextzugriff (PDF)

Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report

Value in health, 2007-09, Vol.10 (5), p.326-335

2007

Volltextzugriff (PDF)

Can’t Get No Satisfaction? Will Pay for Performance Help?: Toward an Economic Framework for Understanding Performance-Based Risk-Sharing Agreements for Innovative Medical Products

PharmacoEconomics, 2010-01, Vol.28 (2), p.93-102

2010

Volltextzugriff (PDF)

Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies

Journal of managed care & specialty pharmacy, 2021-05, Vol.27 (5), p.674-681

2021

Volltextzugriff (PDF)

Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?—An Overview

Value in health, 2016-07, Vol.19 (5), p.512-515

Garrison, Louis P., PhD

2016

Volltextzugriff (PDF)

Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force

Value in health, 2013-07, Vol.16 (5), p.703-719

2013

Volltextzugriff (PDF)

Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold

Journal of managed care & specialty pharmacy, 2019-07, Vol.25 (7), p.793-799

2019

Volltextzugriff (PDF)

Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics

Journal of personalized medicine, 2017-09, Vol.7 (3), p.10

2017

Volltextzugriff (PDF)

Is the price right? Paying for value today to get more value tomorrow

BMC medicine, 2024-01, Vol.22 (1), p.45-45, Article 45

2024

Volltextzugriff (PDF)

A review of economic issues for gene‐targeted therapies: Value, affordability, and access

American journal of medical genetics. Part C, Seminars in medical genetics, 2023-03, Vol.193 (1), p.64-76

2023

Volltextzugriff (PDF)

Is the world ready for gene therapy?

Haemophilia : the official journal of the World Federation of Hemophilia, 2022-03, Vol.28 (S2), p.5-8

2022

Volltextzugriff (PDF)

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support

Journal of managed care & specialty pharmacy, 2020-04, Vol.26 (4), p.400-406

2020

Volltextzugriff (PDF)

The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis

Value in health, 2022-04, Vol.25 (4), p.558-565

2022

Volltextzugriff (PDF)

Review of Recent US Value Frameworks—A Health Economics Approach: An ISPOR Special Task Force Report [6]

Value in health, 2018-02, Vol.21 (2), p.155-160

2018

Volltextzugriff (PDF)

Does Real Option Value Influence Oncologists’ Treatment Recommendations? A Survey of US Oncologists

Value in health, 2024-08

2024

Volltextzugriff (PDF)

A Strategy to Support Efficient Development and Use of Innovations in Personalized Medicine and Precision Medicine

Journal of managed care & specialty pharmacy, 2019-10, Vol.25 (10), p.1082-1087

2019

Volltextzugriff (PDF)

1 – 25 von 323

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(299)
Mit Volltextzugriff
(260)

Publikationsform

Sprache

Englisch
(322)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]

An Overview of Value, Perspective, and Decision Context—A Health Economics Approach: An ISPOR Special Task Force Report [2]

Multicriteria Decision Analysis and Value Assessment Frameworks: Where Do We Stand? What Next?

Incorporating Real Option Value in Valuing Innovation: A Way Forward

Paying for Kidneys: Reflections on Welfare Economics, Political Economy, and Market Design

Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the “Age of Cures” and Their Implications for Dynamic Efficiency

Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis

A Health Economics Approach to US Value Assessment Frameworks—Introduction: An ISPOR Special Task Force Report [1]

Performance-Based Risk-Sharing Arrangements: An Updated International Review

Estimating the Allocation of the Economic Value Generated by Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015 to 2019

Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report

Can’t Get No Satisfaction? Will Pay for Performance Help?: Toward an Economic Framework for Understanding Performance-Based Risk-Sharing Agreements for Innovative Medical Products

Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies

Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?—An Overview

Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force

Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold

Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics

Is the price right? Paying for value today to get more value tomorrow

A review of economic issues for gene‐targeted therapies: Value, affordability, and access

Is the world ready for gene therapy?

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support

The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis

Review of Recent US Value Frameworks—A Health Economics Approach: An ISPOR Special Task Force Report [6]

Does Real Option Value Influence Oncologists’ Treatment Recommendations? A Survey of US Oncologists

A Strategy to Support Efficient Development and Use of Innovations in Personalized Medicine and Precision Medicine

Suchergebnisse filtern